Building a biotech - ups and downs from Oxford founders
This year we are trying something new and taking our Women in Biotech network to Oxford. We hope to engage with the entrepreneur community in Oxford to inspire more women to take up founding roles and support those that have embarked on that mission. We will be joined by four inspirational founders from Oxford who will talk us through their challenges and successes of starting a biotech company. We are very lucky to have Science Disrupt founder Gemma Milne lead this inspiring discussion.
We look forward to seeing you at the new Oxford BioEscalator for an evening of enlightening discussion and networking.
Agenda
17.45 - 18.30 Registration and networking
18.30 - 19.30 Panel discussion and Q&A
19.30 - 20.30 Networking and drinks
Venue
BioEscalator
Innovation Building
University of Oxford
Roosevelt Drive
Oxford, OX3 7FZ
Gemma Milne is a Science & Technology Writer covering all things deep tech, including biotech, advanced computing, space, energy and innovation in academia, for titles such as Forbes, the BBC, CNBC, the Guardian, and Quartz. She is also Co-Host of Science: Disrupt – a podcast interviewing the innovators, iconoclasts & entrepreneurs creating change in science. As a deep tech consultant, she is an Expert Advisor for the European Commission and Innovate UK, and a Scout for Backed VC. Gemma is an Innovation Jury Member for SXSW and a World Economic Forum Global Shaper, and she is currently writing her first book on hype and idealism in science and tech.
Amy is VP Operations at OxStem, an Oxford-based biotech developing small molecule therapeutics targeting innate regeneration and repair. She obtained her Biochemistry degree from the University of Oxford, before retraining in Organic Chemistry for her DPhil, also at Oxford.
Amy is passionate about translating innovative science into impactful medicines. She joined OxStem as the first employee, assisting with the establishment of the company and its first four subsidiaries.
Caroline Godfrey is Senior Vice President of Discovery. having She is a co-founder of PepGen and led the company as CEO from spinout, successfully raising seed funding of $4.5M and a Series A of $45M. Caroline has deep experience with PepGen’s enhanced delivery oligonucleotide therapeutics, having worked as a post-doctoral researcher developing this proprietary technology at the University of Oxford. Prior to this, Dr Godfrey worked in genetics in a the private and NHS settings, and received her PhD from University College London following research in the field of neuromuscular diseases.
Cost
BIA members - £25 + VAT
Non-members - £35 + VAT
BIA emerging companies or early stage non-member companies (in a company with less than 10 employees) or a university researcher - £20 + VAT *